PE46197A1 - METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES - Google Patents

METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES

Info

Publication number
PE46197A1
PE46197A1 PE00009596A PE00009596A PE46197A1 PE 46197 A1 PE46197 A1 PE 46197A1 PE 00009596 A PE00009596 A PE 00009596A PE 00009596 A PE00009596 A PE 00009596A PE 46197 A1 PE46197 A1 PE 46197A1
Authority
PE
Peru
Prior art keywords
vertebral
risk
decrease
alendronate
women
Prior art date
Application number
PE00009596A
Other languages
Spanish (es)
Inventor
David B Karpf
Thomas P Capizzi
Ii Arthur C Santora
Deborah Ruth Shapiro
Ashley John Yates
Desmond E Thompson
Hui Quan
William J Polvino
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27409915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE46197(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/389,860 external-priority patent/US20010051616A1/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE46197A1 publication Critical patent/PE46197A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

QUE APLICADO EN MUJERES OSTEROPOROSICAS, COMPRENDE ADMINISTRAR ORALMENTE UNA CANTIDAD DIARIA DE 5 mg A 20 mg DE ALENDRONATO O UNA SAL FARMACEUTICAMENTE ACEPTABLE POR UN PERIODO DE AL MENOS TRES ANOS; CUANDO SE ADMINISTRA ORALMENTE ANTES DE LA FRACTURA EN UNA DOSIS DIARIA Y POR UN PERIODO SIMILAR A LO ANTERIOR EL ALENDRONATO PUEDE REDUCIR LA SEVERIDAD DE LA FRACTURA; ADEMAS PUEDE REDUCIR LA DEFORMACION COLUMNAR Y LA PERDIDA DE ALTURA EN MUJERES OSTEOPOROSICAS MEDIANTE ADMINISTRACION ORALWHICH APPLIED TO WOMEN WITH OSTEROPOROSICS, IT INCLUDES ORALLY ADMINISTERING A DAILY AMOUNT OF 5 mg TO 20 mg OF ALENDRONATE OR A PHARMACEUTICALLY ACCEPTABLE SALT FOR A PERIOD OF AT LEAST THREE YEARS; WHEN IT IS ORALALLY ADMINISTERED BEFORE FRACTURE IN A DAILY DOSE AND FOR A PERIOD SIMILAR TO THE ABOVE, ALENDRONATE CAN REDUCE THE SEVERITY OF FRACTURE; FURTHER IT CAN REDUCE THE COLUMNARY DEFORMATION AND THE LOSS OF HEIGHT IN OSTEOPOROSIC WOMEN BY ORAL ADMINISTRATION

PE00009596A 1995-02-17 1996-02-12 METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES PE46197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39046295A 1995-02-17 1995-02-17
US08/389,860 US20010051616A1 (en) 1995-02-17 1995-02-17 Method of lessening the risk of vertebral fractures
US41963195A 1995-04-10 1995-04-10

Publications (1)

Publication Number Publication Date
PE46197A1 true PE46197A1 (en) 1997-11-28

Family

ID=27409915

Family Applications (1)

Application Number Title Priority Date Filing Date
PE00009596A PE46197A1 (en) 1995-02-17 1996-02-12 METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES

Country Status (9)

Country Link
AR (1) AR002707A1 (en)
CO (1) CO4920257A1 (en)
CZ (1) CZ259097A3 (en)
DZ (1) DZ1991A1 (en)
HR (1) HRP960080A2 (en)
IL (1) IL117077A (en)
PE (1) PE46197A1 (en)
TW (1) TW453880B (en)
YU (1) YU8896A (en)

Also Published As

Publication number Publication date
IL117077A0 (en) 1996-06-18
IL117077A (en) 2002-08-14
YU8896A (en) 1999-12-27
TW453880B (en) 2001-09-11
HRP960080A2 (en) 1997-10-31
DZ1991A1 (en) 2002-07-20
CZ259097A3 (en) 1997-11-12
AR002707A1 (en) 1998-04-29
CO4920257A1 (en) 2000-05-29

Similar Documents

Publication Publication Date Title
ES2170069T3 (en) 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION.
ES2188782T3 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE.
CU23468B7 (en) DOSAGE FORM OF PRAMIPEXOL IN A SINGLE DAILY DOSE
DK0833643T3 (en) Formulations of anhydrous monosodium salt of alendronate and their use in the treatment of bone disorders
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
BR9909672A (en) use of an active medicinal compound in the preparation of a medicament for the treatment of hypertension
ES2096781T3 (en) COMPOSITIONS OF CONTROLLED RELEASE OXICODONS.
BR9405843A (en) Process to reduce bone loss and use of a compound
RU2008103617A (en) BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS
CY2512B1 (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
AR020803A1 (en) A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE
RU2003105159A (en) METHOD FOR TREATING CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER MENOPAUSE
BR0114100A (en) Controlled release formulations for oral administration
CA2416480A1 (en) Method for the treatment of climacteric disorders in women during or after the menopause
CO5540323A2 (en) ORAL ADMINISTRATION OF HORMONE PARATIROIDES AND CALCITONINE
ES2175663T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS.
AR037524A1 (en) DOSAGE UNIT INCLUDING A PROSTAGLANDINE ANALOG FOR THE CONSTIPATION TREATMENT
NO962752L (en) Use of 2,3-diaryl-1-benzopyran derivatives in the manufacture of a medicament for the treatment and prevention of bone loss and osteoporosis
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
ES2115571T3 (en) USE OF PENTOSANA POLISULFATE FOR THE RESOLUTION OF SCARS IN CHRONIC PROGRESSIVE VASCULAR DISEASES.
CA2497353A1 (en) Method for preventing or reducing secondary fractures after hip fracture
PE46197A1 (en) METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES
US5914099A (en) Prevention of tooth loss by the administration of alendronate or its salts
RU2003100081A (en) METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY
US20050101673A1 (en) Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas

Legal Events

Date Code Title Description
FC Refusal